Channelchek - Looking for the next apple? This is the orchard.

ZOMDF

$0.09

(2.65%)

FLWS

$4.08

(4.08%)

ACCO

$4.18

(5.29%)

ARLP

$24.59

(0.08%)

AUIAF

$0.15

(1.87%)

AZZ

$151.14

(0.45%)

BTBT

$1.47

(-6.96%)

BTM

$0.49

(0%)

CVKD

$2.33

(-0.85%)

LCE:CA

$0.24

(-2%)

COCP

$0.95

(-1.03%)

CDRO

$9.52

(-0.73%)

CVGI

$4.69

(-2.09%)

LODE

$3.94

(-5.29%)

CMTL

$1.66

(-5.14%)

CNDT

$1.58

(3.95%)

CXW

$30.65

(-1.42%)

CMLS

$0.01

(0%)

DRCT

$2.38

(-7.75%)

DLHC

$5.57

(3.53%)

SSP

$3.13

(1.29%)

ELDN

$3.84

(-4.48%)

EVC

$10.51

(-5.06%)

EDRY

$22.35

(-2.78%)

ESEA

$71.73

(0.39%)

FAT

$0.16

(0%)

RAIL

$7.73

(-2.89%)

GDEV

(0%)

GOVX

$0.87

(-13.82%)

GOCO

$0.3

(0%)

GHM

$108.15

(-1.86%)

GLDD

$17

(0%)

GYRE

$7.58

(-1.88%)

HMENF

$1.87

(-1.16%)

III

$4.1

(3.27%)

IPOOF

$10.39

(-2.53%)

KELYA

$15.41

(7.54%)

KTOS

$46.96

(-5.48%)

LUCK

$7.27

(1.11%)

MAIA

$1.33

(-9.52%)

MGROF

$0.26

(0%)

NTRB

$3.13

(2.62%)

OCGN

$1.37

(-4.2%)

PERF

$1.92

(0%)

QMCI

$0.15

(0%)

RGP

$4.69

(2.18%)

SGA

$9.18

(-0.92%)

SHWZ

(0%)

SHIP

$14.81

(-2.76%)

SLQT

$0.72

(-3.9%)

SKYX

$1.18

(-5.6%)

SNAL

$5.14

(3.42%)

GEO

$29.62

(-0.67%)

ODP

$28

(0%)

TNXP

$11.85

(2.07%)

TSQ

$6.74

(-0.59%)

TZOO

$11

(-0.72%)

UNCY

$5.05

(0.6%)

VVX

$75.05

(-0.79%)

VNCE

$6.38

(3.57%)

XELB

$1.39

(-6.08%)

ZOMDF

$0.09

(2.65%)

FLWS

$4.08

(4.08%)

channelchek-in

‌

7/16/2026

Eli Lilly Pays $3.8 Billion for AtaiBeckley as Big Pharma’s Push Into Mental Health Enters a New Phase

The pharmaceutical industry’s appetite for neuroscience innovation just produced one of the most significant mental health deals in years. Eli Lilly (NYSE: LLY) announced Wednesday it has entered into a definitive agreement to acquire AtaiBeckley (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing rapid-acting therapies for treatment-resistant depression and other serious mental health conditions. The deal values AtaiBeckley at approximately $2.8 billion in upfront equity consideration, with an additional $1.0 billion in potential milestone-based contingent value rights, bringing the total potential transaction value to approximately $3.8 billion.

3 min read